Trump Touts Medicaid Drug Price Program With State Buy-In

President Trump publicly promoted a federal program designed to lower prescription drug prices within Medicaid, announcing that every state had opted into the initiative ahead of the midterm elections. The program seeks to bring Medicaid's medicine costs in line with prices paid by other high-income countries, a model often referred to as international reference pricing.

The administration's push comes as drug pricing remains a politically sensitive issue for voters across party lines. By securing participation from all states, the White House positioned the effort as a rare example of broad governmental consensus on a persistently contentious policy challenge.

Read more SEC Chair Atkins Moves to Eliminate Shareholder Proposal Rule →

Medicaid, the federal-state health insurance program covering tens of millions of lower-income Americans, has long faced scrutiny over the prices it pays for pharmaceuticals relative to peer nations. Aligning those costs with international benchmarks could represent significant savings for both the federal government and state budgets, though critics and industry groups have historically resisted such comparisons as potentially limiting patient access to new medicines.

The timing of the announcement — with midterm elections on the horizon — underscores the political salience of health care costs as a campaign issue. Drug pricing policy has drawn bipartisan attention in recent years, and the administration appeared eager to claim a concrete achievement in an area where legislative progress has repeatedly stalled.

Continue reading at NYT > Business.